CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
Talazoparibdrug
Likely dose
Talazoparib 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03042910
NCT03042910Phase 1Completed
CompareCT.gov

A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE EFFECTS OF TALAZOPARIB ON CARDIAC REPOLARIZATION IN PATIENTS WITH ADVANCED SOLID TUMORS

Pfizer·interventional·Posted Feb 3, 2017·Updated Dec 17, 2019

In Brief

A Phase 1 clinical trial evaluating Talazoparib for Solid Tumor. Completed, enrolled 38 participants across 19 sites.

Detailed Summary

This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesUnited States
CollaboratorsMedivation, Inc.

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 3, 2017
Enrollment StartOct 13, 2016
Primary CompletionMay 30, 2017
Study CompletionJun 22, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.4 years ago

Interventions

Talazoparibdrug

Talazoparib 1 mg orally once daily.